Kesimpta key to Novartis' further guidance upgrade

24 October 2023

Novartis (NOVN: VX) has lifted its 2023 earnings forecast for the third time.

This came after what chief executive Vas Narasimhan called a “very strong quarter” for the Swiss pharma giant.

"We have successfully executed the spin-off of Sandoz, allowing us to fully focus on high-value innovative medicines" Group sales rose by 12% to $11.78 billion, driven by a more than doubling in revenue raised by the multiple sclerosis drug Kesimpta (ofatumumab) due to increased demand, strong access and a one-time revenue deduction adjustment in Europe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK